TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria to Treat Fatal Diseases w/ Affordable Drug - LDN

FINALLY!!!!  ANOTHER one... Oh man ...I can't take it! Another Happy articles !!!.  Thank you God!  lol

This drug, LDN, will work wonders for the diseases killing the population of Nigeria.  It's been years and years of waiting on a drug that wouldn't work well, but be within a decent price range.  Finally these people will get the help they need that will hopefully extend their lives and improve the quality of them as well.  

ARTICLE HIGHLIGHTS

• According to Frank Aribeana, the managing member of G-Ex Technologies/St Maris Pharma, "We are delighted to enter into this agreement as we believe the introduction of IRT-103 LDN and IRT-104 LDN cream in this market will allow us to provide much needed treatment at an affordable price to the citizens of the Federal Republic of Nigeria."     E P I C   N E W S
• TNI BioTech, Inc., is a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.
• most advanced clinical programs involve immunotherapy that works by isolating a patient's lymphocytes and then incubating them together with Methionine Enkephalin (MENK) in an enriching external incubation system. After incubation the patient's lymphocytes are re-infused back into the patient where they combat and destroy tumor cells.
  
  Read more here: http://www.sacbee.com/2012/11/15/4988198/tni-biotech-inc-signs-exclusive.html#storylink=cpy
  
  Read more here: http://www.sacbee.com/2012/11/15/4988198/tni-biotech-inc-signs-exclusive.html#storylink=cpy

TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC

By TNI BioTech, Inc.

Published: Thursday, Nov. 15, 2012 - 6:31 am

NEW YORK, Nov. 15, 2012 -- /PRNewswire/ -- TNI BioTech, Inc. (Pinksheets: TNIB) announced today the signing of an exclusive distributor agreement with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC for the Federal Republic of Nigeria.  Under the terms of the agreement, G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC will have exclusive marketing and distribution rights to IRT-103 LDN and IRT-104 LDN cream in Nigeria. TNIB will be responsible for the manufacture and supply of IRT-103 LDN and IRT-104 LDN cream. The therapies, developed as a treatment for cancer, HIV/AIDS and other autoimmune diseases, will be manufactured in TNI BioTech, Inc.'s facility in Managua, Nicaragua under the supervision and quality control of Dr. Henry "Skip" Lenz.  G-Ex Technologies/St. Maris Pharma, as part of the agreement, will provide TNIB with a revolving letter of credit for the minimum purchase of 750,000 doses monthly of IRT-103 LDN or IRT-104 LDN cream beginning March 1, 2013 priced at $1.00 dollar per dose. 

The agreements calls for G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC to purchase a minimum of 15,000,000 doses monthly within 24 months to maintain their exclusive agreement. Once G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC reach sales of 1,000,000 million doses per day TNIB has agreed to joint venture a factory in the Federal Republic of Nigeria to meet local demands.

Noreen Griffin, CEO of TNI BioTech, Inc. said "this contract shows TNI BioTech's commitment to generate revenue during our first year of operations."

According to Frank Aribeana, the managing member of G-Ex Technologies/St Maris Pharma, "We are delighted to enter into this agreement as we believe the introduction of IRT-103 LDN and IRT-104 LDN cream in this market will allow us to provide much needed treatment at an affordable price to the citizens of the Federal Republic of Nigeria."

About G-Ex Technologies/St. Maris Pharma G.Ex Technologies/St. Maris Pharma is a consortium of management consultant, general pharmaceutical, clinical pharmacy and marketing executives, each with over twenty-five years of industry experience and well versed in the changing dynamics of the prescription and OTC drug international marketplace. Actively supported by medical practice professionals in business and academia who have been involved in the management of related drug therapies for many years, the consortium is poised to champion the successful introduction of IRT-103 LDN and IRT-104 LDN in the territory.  

About TNI BioTech, Inc. TNI BioTech, Inc., is a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.

Our proprietary technology, therapies and patents, will be used to treat a wide range of cancers. Our most advanced clinical programs involve immunotherapy that works by isolating a patient's lymphocytes and then incubating them together with Methionine Enkephalin (MENK) in an enriching external incubation system. After incubation the patient's lymphocytes are re-infused back into the patient where they combat and destroy tumor cells.

Even though Management considers any condition that results in altered-immune response a target for investigation, the Company will most likely pursue additional investigations for MENK as a valuable candidate in the treatment of the following:

• Autoimmune states such as rheumatoid arthritis and multiple sclerosis;
• As an adjunct to antibiotics in the treatment of infectious diseases;
• In cancer patients undergoing chemotherapy, radiation treatments or surgery;
• Patients with AIDS, in combination with retroviral drug therapy; and
• In wound healing or herpes viral infections.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release includes various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company's expectations or beliefs concerning future events. Statements containing expressions such as "believes," "anticipates," "intends," or "expects," used in the Company's press releases and in Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve risks and uncertainties. Although the Company believes its expectations are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there can be no assurances that actual results will not differ materially from expected results. The Company cautions that these and similar statements included in this report are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof. Contact: Global Investment Media

Phone:  310-353-6277

SOURCE TNI BioTech, Inc.

Read more here: http://www.sacbee.com/2012/11/15/4988198/tni-biotech-inc-signs-exclusive.html#storylink=cpy

TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC - PR Newswire - The Sacramento Bee:

'via Blog this'

Mycobacterium avium subspecies paratuberculosis (MAP) "suspected as a causative agent in Crohn's disease"

Hmmmmm... interesting.  My friend happened to stumble upon this on Wikipedia when she was reading about milk pasteurization (totally unrelated to Crohn's).  I thought that milk is supposed to do our body good.. Well, that's what they used to say.  And if this is a possible cause of Crohn's disease (because remember no one knows the cause of Crohn's), why are they not doing more research to find out for sure.  

Maybe this explains why children as young as 3 or 4 years old get Crohn's Disease.  The whole time they are sippin on their yummy warm milk in their bottle or sippy cup, they're possibly swallowing some MAP, which is a stubborn, resistant bastard.    That could explain where Crohn's gets it's stubbornness from.  

Just  thought this was something to think about. Feel free to leave opinions  :)

MAP causes Johne's disease in cattle and other ruminants, and it has long been suspected as a causative agent in Crohn's disease in humans;^[3] this connection is controversial.^[4]

Recent studies have shown that MAP present in milk can survive pasteurization, which has raised human health concerns due to the widespread nature of MAP in modern dairy herds. MAP survival during pasteurization is dependent on the D_72C-value of the strains present and their concentration in milk. It is heat resistant and is capable of sequestering itself inside white blood cells, which may contribute to its persistence in milk. It has also been reported to survive chlorination in municipal water supplies.

Even though MAP is hardy, it is slow growing and fastidious, which means it is difficult to culture. Many negative studies for MAP presence in living tissue, food, and water have used culture methods to determine whether the bacteria are present. Due to recent advances in our knowledge of the bacterium, some or all of these studies may need to be re-evaluated on the basis of culture methodology.

MAP infections, like with most mycobacteria, are difficult to treat. It is not susceptible to antituberculosis drugs (which can generally kill Mycobacterium tuberculosis), but can only be treated with a combination of antibioticssuch as rifabutin and a macrolide such as clarithromycin. Treatment regimens can last years.^[5][6]

[edit]Crohn's disease

MAP is recognized as a multi-host mycobacterial pathogen with a proven specific ability to initiate and maintain systemic infection and chronic inflammation of the intestine of a range of histopathological types in many animal species, including primates.^[7]

On the assumption that MAP is a causative agent in Crohn's disease, the Australian biotechnology company Giaconda is seeking to commercialize a combination of rifabutin, clarithromycin, and clofazimine as a potential drug therapy, called Myoconda, for Crohn's. As of April 2007, Giaconda received United States FDA IND approval for a new Phase 2/3 trial.^[8]

MAP has been found in larger numbers within the intestines of Crohn's disease patients^[9] than those with ulcerative colitis and healthy controls.

http://en.wikipedia.org/wiki/Mycobacterium_avium_subspecies_paratuberculosis